Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Leronlimab |
| Trade Name | |
| Synonyms | PRO140|PRO 140|anti-CCR5 antibody |
| Drug Descriptions |
Leronlimab is a monoclonal antibody that targets CCR5, which potentially induces killing of tumor cells expressing CCR5, inhibits invasion and metastasis, and reduces tumor burden (Cancer Res 2020;80(4 Suppl):Abstract nr PD4-04). |
| DrugClasses | |
| CAS Registry Number | 674782-26-4 |
| NCIT ID | C137824 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + Leronlimab + Trifluridine-tipiracil hydrochloride | Bevacizumab Leronlimab Trifluridine-tipiracil hydrochloride | 0 | 1 |
| Carboplatin + Leronlimab | Carboplatin Leronlimab | 0 | 1 |
| Leronlimab | Leronlimab | 0 | 1 |